Pharvaris (PHVS) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$31.10
-0.1% on the day
+36.2% over 12 months
52-week range $20.96 – $38.86
Share price and insider trades
PHVS closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$33.0M
Insiders buying0
Insiders selling11
Pharvaris insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 11 sold $33.0M of PHVS stock on the open market.
Get emailed when insiders cluster-buy stocks like PHVS
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
PHVS insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | — | 0 |
| Q3 2026 | — | 0 | $20.5M | 20 |
| Q2 2026 | — | 0 | $12.5M | 51 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Pharvaris N.V. insiders reported open-market purchases totaling $0, while 11 insiders reported sales totaling $33.0M. 54 of 71 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Sep 25SEC | Viviane MongesDirector | Sell | 11,9695,500 held (−69%) | $33.05 | $396K | -5.9% | — |
| Sep 24SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell | 800115,167 held (−1%) | $36.19 | $29K | -14.1% | — |
| Sep 23SEC | David W. NassifCFO, General Counsel | Sell | 6,000114,300 held (−5%) | $36.47 | $219K | -14.7% | — |
| Sep 21SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell | 200,000115,167 held (−63%) | $35.00 | $7.0M | -11.1% | — |
| Sep 21SEC | Peng LuPresident | Sell | 100,00064,953 held (−61%) | $35.00 | $3.5M | -11.1% | — |
| Sep 21SEC | Elisabeth BjorkDirector | Sell | 52,50015,167 held (−78%) | $37.89 | $2.0M | -17.9% | — |
| Sep 21SEC | Anne LesageChief Early Development | Sell | 20,00073,969 held (−21%) | $38.27 | $765K | -18.7% | — |
| Sep 21SEC | Robert GlassmanDirector | Sell Plan | 14,49310,500 held (−58%) | $38.56 | $559K | -19.3% | — |
| Sep 17SEC | Stefan Andreas AbeleChief Technical Ops Officer | Sell | 45,00040,468 held (−53%) | $38.14 | $1.7M | -18.5% | — |
| Sep 17SEC | Robert GlassmanDirector | Sell Plan | 8,66710,500 held (−45%) | $38.27 | $332K | -18.7% | — |
| Sep 17SEC | Stefan Andreas AbeleChief Technical Ops Officer | Sell | 1,40039,068 held (−3%) | $39.24 | $55K | -20.7% | — |
| Sep 16SEC | Wim SouverijnsChief Commercial Officer | Sell Plan | 20,00045,111 held (−31%) | $39.31 | $786K | -20.9% | — |
| Sep 16SEC | Wim SouverijnsChief Commercial Officer | Sell Plan | 6,09039,021 held (−14%) | $38.99 | $237K | -20.2% | — |
| Sep 15SEC | Peng LuPresident | Sell Plan | 15,00065,179 held (−19%) | $40.13 | $602K | -22.5% | — |
| Sep 15SEC | Berndt ModigCEO | Sell Plan | 2,291128,334 held (−2%) | $39.40 | $90K | -21.1% | — |
| Sep 14SEC | Anne LesageChief Early Development | Sell Plan | 30,00056,450 held (−35%) | $38.30 | $1.1M | -18.8% | — |
| Sep 11SEC | Robert GlassmanDirector | Sell Plan | 8,00010,500 held (−43%) | $37.55 | $300K | -17.2% | — |
| Sep 9SEC | Peng LuPresident | Sell Plan | 15,00065,179 held (−19%) | $40.68 | $610K | -23.5% | — |
| Aug 18SEC | Berndt ModigCEO | Sell Plan | 2,292130,625 held (−2%) | $34.77 | $80K | -10.6% | — |
| Jul 15SEC | Berndt ModigCEO | Sell Plan | 2,292132,917 held (−2%) | $34.97 | $80K | -11.1% | — |
| Jul 1SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 30,712315,167 held (−9%) | $35.49 | $1.1M | -12.4% | — |
| Jul 1SEC | Anne LesageChief Early Development | Sell Plan | 30,70393,969 held (−25%) | $35.49 | $1.1M | -12.4% | — |
| Jul 1SEC | Anne LesageChief Early Development | Sell Plan | 27,87258,750 held (−32%) | $35.48 | $989K | -12.3% | — |
| Jul 1SEC | Anne LesageChief Early Development | Sell Plan | 8,30058,750 held (−12%) | $35.05 | $291K | -11.3% | — |
| Jul 1SEC | Anne LesageChief Early Development | Sell Plan | 6,997124,672 held (−5%) | $35.05 | $245K | -11.3% | — |
| Jul 1SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 6,888345,879 held (−2%) | $35.05 | $241K | -11.3% | — |
| Jul 1SEC | Anne LesageChief Early Development | Sell Plan | 2,30056,450 held (−4%) | $35.12 | $81K | -11.4% | — |
| Jun 29SEC | Peng LuChief Medical Officer | Sell Plan | 14,70065,631 held (−18%) | $34.00 | $500K | -8.5% | — |
| Jun 29SEC | Peng LuChief Medical Officer | Sell Plan | 11,60069,031 held (−14%) | $34.45 | $400K | -9.7% | — |
| Jun 29SEC | Peng LuChief Medical Officer | Sell Plan | 3,40065,631 held (−5%) | $35.09 | $119K | -11.4% | — |
| Jun 29SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 2,400352,767 held (−1%) | $35.10 | $84K | -11.4% | — |
| Jun 29SEC | Anne LesageChief Early Development | Sell Plan | 2,30056,450 held (−4%) | $35.12 | $81K | -11.4% | — |
| Jun 29SEC | Anne LesageChief Early Development | Sell Plan | 2,300131,669 held (−2%) | $35.12 | $81K | -11.4% | — |
| Jun 23SEC | Peng LuChief Medical Officer | Sell Plan | 30065,631 held (−0%) | $34.00 | $10K | -8.5% | — |
| Jun 17SEC | Berndt ModigCEO | Sell Plan | 2,191135,309 held (−2%) | $31.05 | $68K | +0.2% | — |
| Jun 17SEC | Berndt ModigCEO | Sell Plan | 100135,209 held (−0%) | $31.46 | $3K | -1.1% | — |
| Jun 8SEC | Anna NijdamPrincipal Accounting Officer | Sell | 2,67046,275 held (−5%) | $30.87 | $82K | +0.7% | — |
| May 26SEC | David W. NassifCFO, General Counsel | Sell | 10,000120,300 held (−8%) | $30.31 | $303K | +2.6% | — |
| May 26SEC | Viviane MongesDirector | Sell | 9,6675,500 held (−64%) | $30.29 | $293K | +2.7% | — |
| May 26SEC | Anna NijdamPrincipal Accounting Officer | Sell | 5,50148,945 held (−10%) | $30.74 | $169K | +1.2% | — |
| May 26SEC | Anna NijdamPrincipal Accounting Officer | Sell | 1,82948,945 held (−4%) | $30.60 | $56K | +1.6% | — |
| May 22SEC | Elisabeth BjorkDirector | Sell Plan | 10,00015,167 held (−40%) | $29.32 | $293K | +6.1% | — |
| May 20SEC | Berndt ModigCEO | Sell Plan | 2,292137,500 held (−2%) | $29.22 | $67K | +6.4% | — |
| May 19SEC | Wim SouverijnsChief Commercial Officer | Sell Plan | 10,00045,111 held (−18%) | $29.92 | $299K | +3.9% | — |
| May 19SEC | Stefan Andreas AbeleChief Technical Ops Officer | Sell | 8,74835,194 held (−20%) | $29.82 | $261K | +4.3% | — |
| May 19SEC | Robert GlassmanDirector | Sell | 5,33315,167 held (−26%) | $29.83 | $159K | +4.3% | — |
| May 19SEC | Robert GlassmanDirector | Sell | 4,66710,500 held (−31%) | $29.82 | $139K | +4.3% | — |
| May 5SEC | Peng LuChief Medical Officer | Sell Plan | 14,02366,226 held (−17%) | $30.16 | $423K | +3.1% | — |
| May 5SEC | Peng LuChief Medical Officer | Sell Plan | 14366,083 held (−0%) | $31.00 | $4K | +0.3% | — |
| May 1SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 28,400355,837 held (−7%) | $30.30 | $861K | +2.6% | — |
| May 1SEC | Anne LesageChief Early Development | Sell Plan | 19,200133,969 held (−13%) | $30.26 | $581K | +2.8% | — |
| May 1SEC | Anne LesageChief Early Development | Sell Plan | 18,00056,450 held (−24%) | $30.26 | $545K | +2.8% | — |
| May 1SEC | Peng LuChief Medical Officer | Sell Plan | 15,00066,083 held (−18%) | $30.24 | $454K | +2.8% | — |
| May 1SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 3,830384,237 held (−1%) | $30.07 | $115K | +3.4% | — |
| May 1SEC | Peng LuChief Medical Officer | Sell Plan | 3,73362,350 held (−6%) | $30.06 | $112K | +3.5% | — |
| May 1SEC | Anne LesageChief Early Development | Sell Plan | 3,70056,450 held (−6%) | $30.26 | $112K | +2.8% | — |
| May 1SEC | Anne LesageChief Early Development | Sell Plan | 3,70056,450 held (−6%) | $30.08 | $111K | +3.4% | — |
| May 1SEC | Anne LesageChief Early Development | Sell Plan | 3,700153,169 held (−2%) | $30.06 | $111K | +3.5% | — |
| May 1SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 670355,167 held (−0%) | $31.03 | $21K | +0.2% | — |
| Apr 24SEC | Peng LuChief Medical Officer | Sell Plan | 7,00166,083 held (−10%) | $30.05 | $210K | +3.5% | — |
| Apr 24SEC | Anne LesageChief Early Development | Sell Plan | 7,00056,450 held (−11%) | $30.05 | $210K | +3.5% | — |
| Apr 24SEC | Anne LesageChief Early Development | Sell Plan | 7,000156,969 held (−4%) | $30.05 | $210K | +3.5% | — |
| Apr 24SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 7,000388,167 held (−2%) | $30.05 | $210K | +3.5% | — |
| Apr 24SEC | Anne LesageChief Early Development | Sell Plan | 50056,450 held (−1%) | $30.00 | $15K | +3.7% | — |
| Apr 24SEC | Anne LesageChief Early Development | Sell Plan | 100156,869 held (−0%) | $30.03 | $3K | +3.6% | — |
| Apr 24SEC | Anne LesageChief Early Development | Sell Plan | 10056,450 held (−0%) | $30.03 | $3K | +3.6% | — |
| Apr 24SEC | Peng LuChief Medical Officer | Sell Plan | 10066,083 held (−0%) | $30.03 | $3K | +3.6% | — |
| Apr 24SEC | Johannes Gerardus Christiaan Petrus SchikanDirector | Sell Plan | 100388,067 held (−0%) | $30.03 | $3K | +3.6% | — |
| Apr 20SEC | Berndt ModigCEO | Sell Plan | 2,292139,792 held (−2%) | $28.60 | $66K | +8.7% | — |
| Apr 10SEC | Berndt ModigCEO | Sell Plan | 23,133142,284 held (−14%) | $27.74 | $642K | +12.1% | — |
| Apr 10SEC | Berndt ModigCEO | Sell Plan | 200142,084 held (−0%) | $28.42 | $6K | +9.4% | — |
Insiders at Pharvaris N.V.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Johannes Gerardus Christiaan Petrus SchikanDirector | — | $9.7M | Sep 24, 2026 | — |
| Peng LuPresident | — | $6.9M | Sep 21, 2026 | — |
| Anne LesageChief Early Development | — | $6.7M | Sep 21, 2026 | — |
| Elisabeth BjorkDirector | — | $2.3M | Sep 21, 2026 | — |
| Stefan Andreas AbeleChief Technical Ops Officer | — | $2.0M | Sep 17, 2026 | — |
| Robert GlassmanDirector | — | $1.5M | Sep 21, 2026 | — |
| Wim SouverijnsChief Commercial Officer | — | $1.3M | Sep 16, 2026 | — |
| Berndt ModigCEO | — | $1.1M | Sep 15, 2026 | — |
| Viviane MongesDirector | — | $688K | Sep 25, 2026 | — |
| David W. NassifCFO, General Counsel | — | $522K | Sep 23, 2026 | — |
| Anna NijdamPrincipal Accounting Officer | — | $307K | Jun 8, 2026 | — |
PHVS stock: common questions
Are Pharvaris N.V. insiders buying PHVS stock?
In the past 12 months, 0 insiders reported open-market purchases of PHVS worth $0.
Are Pharvaris N.V. insiders selling PHVS stock?
11 insiders reported sales worth $33.0M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is PHVS's 52-week range?
Over the past year PHVS has traded between $20.96 and $38.86. It last closed at $31.10 on Oct 9, 2026.